Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00026156 · ClinicalTrials.gov registry record · Phase 2

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

A Phase 2 study, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
125
Enrollment target

NCT00026156: Completed Phase 2 study, sponsored by SWOG Cancer Research Network.

NCT00026156 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 125 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00026156, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
125 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine followed by docetaxel in treating patients who have advanced non-small cell lung cancer.

Interventions

  • DRUG docetaxel
  • DRUG vinorelbine tartrate

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2001-11
Est. Completion 2008-11
Phase Phase 2
SWOG Cancer Research Network

270 total trials

What the finished NCT00026156 record still lists

NCT00026156 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.

NCT00026156 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00026156 about?

NCT00026156 is a clinical study titled "S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine followed by docetaxel in treating patients who have advanced non-small cell lung cancer.

What is the current status of trial NCT00026156?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2001-11. Estimated completion is 2008-11.

What interventions are being tested in trial NCT00026156?

The interventions under investigation include: docetaxel (DRUG), vinorelbine tartrate (DRUG).

Who is sponsoring clinical trial NCT00026156?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00026156's enrollment target sits among peer trials

125 558th of 2000 higher than 1,437 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02717039 · 125 participants

    Pharmacogenomics of Heparin-Induced Thrombocytopenia

  • NCT02763033 · 125 participants · Phase 2

    Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

  • NCT02793999 · 125 participants

    Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia

  • NCT03003299 · 125 participants · NA

    PARTNER 3 Trial - Aortic Valve-in-Valve

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00026156, the US trial registry maintained by the National Library of Medicine. NCT00026156 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.